IL308669A - Methods of treating mitochondria-related disorders - Google Patents

Methods of treating mitochondria-related disorders

Info

Publication number
IL308669A
IL308669A IL308669A IL30866923A IL308669A IL 308669 A IL308669 A IL 308669A IL 308669 A IL308669 A IL 308669A IL 30866923 A IL30866923 A IL 30866923A IL 308669 A IL308669 A IL 308669A
Authority
IL
Israel
Prior art keywords
mitochondria
treatment
methods
disorders related
disorders
Prior art date
Application number
IL308669A
Other languages
English (en)
Hebrew (he)
Inventor
Shaharyar Khan
Diane Jorkasky
Original Assignee
Rivus Pharmaceuticals Inc
Shaharyar Khan
Diane Jorkasky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivus Pharmaceuticals Inc, Shaharyar Khan, Diane Jorkasky filed Critical Rivus Pharmaceuticals Inc
Publication of IL308669A publication Critical patent/IL308669A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL308669A 2021-05-20 2022-05-19 Methods of treating mitochondria-related disorders IL308669A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163191321P 2021-05-20 2021-05-20
US202163222841P 2021-07-16 2021-07-16
US202263307515P 2022-02-07 2022-02-07
PCT/US2022/029992 WO2022246039A1 (en) 2021-05-20 2022-05-19 Methods of treating mitochondria-related disorders

Publications (1)

Publication Number Publication Date
IL308669A true IL308669A (en) 2024-01-01

Family

ID=82020295

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308669A IL308669A (en) 2021-05-20 2022-05-19 Methods of treating mitochondria-related disorders

Country Status (14)

Country Link
US (1) US20250177353A1 (https=)
EP (1) EP4340829A1 (https=)
JP (1) JP2024521709A (https=)
KR (1) KR20240021827A (https=)
AU (1) AU2022275935A1 (https=)
BR (1) BR112023024146A2 (https=)
CA (1) CA3219548A1 (https=)
CL (1) CL2023003441A1 (https=)
GE (1) GEAP202416398A (https=)
IL (1) IL308669A (https=)
JO (1) JOP20230298A1 (https=)
MX (1) MX2023013688A (https=)
TW (1) TW202313010A (https=)
WO (1) WO2022246039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150759A1 (en) * 2022-02-07 2023-08-10 Rivus Pharmaceuticals, Inc. Methods of weight loss in a subject with elevated hba1c
TW202515545A (zh) * 2023-08-10 2025-04-16 大陸商深圳君聖泰生物技術有限公司 ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
EP4340829A1 (en) 2024-03-27
KR20240021827A (ko) 2024-02-19
JP2024521709A (ja) 2024-06-04
CL2023003441A1 (es) 2024-05-10
JOP20230298A1 (ar) 2023-11-19
US20250177353A1 (en) 2025-06-05
TW202313010A (zh) 2023-04-01
WO2022246039A1 (en) 2022-11-24
AU2022275935A1 (en) 2023-12-07
BR112023024146A2 (pt) 2024-01-30
CA3219548A1 (en) 2022-11-24
MX2023013688A (es) 2024-02-27
GEAP202416398A (en) 2024-01-25

Similar Documents

Publication Publication Date Title
IL280919A (en) Methods of treating aging-related disorders
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
IL295536A (en) Specific tryptamines for use in the treatment of mood disorders
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
IL304324A (en) Heterocycle derivatives for treating trpm3 mediated disorders
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
EP3873897C0 (en) N-BENZOYL-PHENYLALANINE DERIVATIVES AS INTEGRIN ALPHA4BETA7 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL269174A (en) Methods for treating complement-mediated diseases and disorders
IL259861A (en) Methods and compositions for the treatment of seizure-related disorders
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
HRP20250340T8 (hr) Terapijske upotrebe deuteriranih derivata lanifibranora
IL286268A (en) Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof
EA201690936A1 (ru) Применение цистеамина и его производных для лечения митохондриальных заболеваний
IL270900A (en) Treatment of cutaneous disorders
EP3897641C0 (en) TREATMENT OF MOVEMENT DISORDERS
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
IL308669A (en) Methods of treating mitochondria-related disorders
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
IL263080B (en) Treatment of neurological disorders
PL3727423T3 (pl) Leczenie zaburzeń metabolicznych z użyciem wariantów fgf21
HRP20260248T1 (hr) Derivati sulfopropanske kiseline za liječenje neurodegenerativnih poremećaja
MA53636A (fr) Agent de traitement de troubles dermatologiques
IL309393A (en) Retinal disorders
EP3672593C0 (en) DRUGS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO VASOCONSTRICTION